Organization | Translational Oncology Research International

Translational Oncology Research International Report issue

Foundation Phase 2

Founded: Los Angeles CA United States (1997)

Organization Overview

First Clinical Trial

2003

NCT00095706

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2011

Timeline

NOW

Now

Active Ingredients

Drugs in Phase 2 Trials (16)

bevacizumab (avastin) (5 trials)

capecitabine (xeloda) (1 trial)

carboplatin (paraplatin) (1 trial)

cyclophosphamide (cytoxan) (1 trial)

dasatinib (sprycel) (1 trial)

docetaxel (taxotere) (3 trials)

doxorubicin (Doxil) (1 trial)

erlotinib (tarceva) (3 trials)

everolimus (zortress) (1 trial)

fluorouracil (efudex) (1 trial)

fulvestrant (faslodex) (2 trials)

gemcitabine (gemzar) (1 trial)

lapatinib (tykerb) (1 trial)

leucovorin (1 trial)

oxaliplatin (eloxatin) (1 trial)

trastuzumab (herceptin) (3 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Adenocarcinoma (Phase 2)

Breast Neoplasms (Phase 2)

Carcinoma, Acinar Cell (Phase 2)

Carcinoma, Non-Small-Cell Lung (Phase 2)

Colorectal Neoplasms (Phase 2)

Esophageal Neoplasms (Phase 2)

Lung Neoplasms (Phase 2)

Pancreatic Neoplasms (Phase 2)

Prostatic Neoplasms (Phase 2)

Stomach Neoplasms (Phase 2)

Overview

Highest Phase: Phase 2
# of Trials: 11
# of Trial APIs: 16